Evidence map›Paper›PMID 40709298›Full record

ArticleArXiv2025

Probabilistic Modeling of Antibody Kinetics Post Infection and Vaccination: A Markov Chain Approach.

Rayanne A Luke, Prajakta Bedekar, Lyndsey M Muehling, Glenda Canderan, Yesun Lee, Wesley A Cheng, Judith A Woodfolk, Jeffrey M Wilson, Pia S Pannaraj, Anthony J Kearsley

Abstract readPreprint
In one paragraph

Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rayanne A LukeDepartment of Mathematical Sciences, George Mason University, Fairfax, Virginia, 22030, USA.
Prajakta BedekarInformation Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland, 20899, USA.
Lyndsey M MuehlingDivision of Asthma, Allergy and Immunology, University of Virginia, Charlottesville, Virginia, 22903, USA.
Glenda CanderanDivision of Asthma, Allergy and Immunology, University of Virginia, Charlottesville, Virginia, 22903, USA.
Yesun LeeDepartment of Pediatrics, University of California San Diego, La Jolla, California, 92093, USA.
Wesley A ChengDepartment of Pediatrics, University of California San Diego, La Jolla, California, 92093, USA.
Judith A WoodfolkDivision of Asthma, Allergy and Immunology, University of Virginia, Charlottesville, Virginia, 22903, USA.
Jeffrey M WilsonDivision of Asthma, Allergy and Immunology, University of Virginia, Charlottesville, Virginia, 22903, USA.
Pia S PannarajDepartment of Pediatrics, University of California San Diego, La Jolla, California, 92093, USA.
Anthony J KearsleyInformation Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, Maryland, 20899, USA.

Funding

Longitudinal SARS-CoV-2 mRNA vaccine-induced mucosal, serological, and cellular immunity in children and human milkR01AI173194 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Pia S Pannaraj · 2022 to 2026
$4.0M
Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and DiseaseR21AI160334 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2021 to 2022
$444k
Immune Programs and Related T Cell Mechanisms of Pulmonary Complications After COVID-19 IllnessR56AI178669 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2023 to 2023
$410k
NIAID NIH HHS R01 AI173194NIAID NIH HHS R21 AI160334NIAID NIH HHS R56 AI178669
6 · The paper itself

Abstract

Understanding dynamics of antibody levels is crucial for characterizing time-dependent response to immune events: either infections or vaccinations. The sequence and timing of these events significantly influence antibody level changes. Despite extensive interest in the recent years and many experimental studies, the effect of immune event sequences on antibody levels is not well understood. Moreover, disease or vaccination prevalence in the population are time-dependent. This, alongside the complexities of personal antibody kinetics, makes it arduous to analyze a sample immune measurement from a population. A rigorous mathematical characterization can inform public health decision making. Relevance to Life Sciences: A key result of this paper is an antibody response modeling framework for an arbitrary number of multiclass immune events-the first of its kind to the best of our knowledge. Our model is ideal for characterizing immune event sequences, referred to as personal trajectories. To illustrate our ideas, we apply our mathematical framework to longitudinal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) data from individuals with multiple documented infection and vaccination events. This approach is fully generalizable to other diseases that exhibit waning immunity, such as influenza, respiratory syncytial virus (RSV), and pertussis. Our work is an important step towards a comprehensive understanding of antibody kinetics for infectious diseases that could lead to an effective way to analyze the protective power of natural immunity or vaccination, predict missed immune events at an individual level, and inform booster timing recommendations. Mathematical Content: We design a rigorous mathematical characterization in terms of a time-inhomogeneous Markov chain model for event-to-event transitions coupled with a probabilistic framework for the post-event antibody kinetics of multiple immune events. Probabilistic models appropriately describe these measurements as they capture the natural variability in a population's antibody response. We build probability density models for population response since the emergence of a disease via a discrete convolution of immune state transmission probabilities and personal response models, repeatedly invoking the definition of conditional probability and the law of total probability. Importantly, our coupled framework simultaneously tracks immune state and antibody response. This novel modeling approach surpasses the susceptible-infected-recovered (SIR) characterizations by rigorously tracing the probability distribution of population antibody response across time.

Identifiers

PMID40709298
PMCPMC12288654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.